Science raises $400M to expand BCI vision device in US and Europe

Science Corporation has successfully raised $400 million to advance its brain-computer interface technology in Europe and prepare for its introduction in the United States. This funding, part of a Series D round, will support the broader rollout of its Prima BCI device, which obtained CE certification and debuted in Europe in July as a solution for vision impairment.
The Prima system comprises a retinal implant and specialized glasses equipped with a camera. This camera captures and processes visual data, which is then transmitted to the implant via near-infrared light. Upon activation, the implant stimulates retinal nerve cells, enabling them to relay visual information to the brain. With a total investment exceeding $900 million, including $230 million secured in March, Science is targeting U.S. market entry through the humanitarian device exemption pathway.
This latest funding follows a significant investment surge for Science, which has amassed $630 million since publishing a key paper late last year. The Series D round attracted participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. Post-CE certification, the company initiated national reimbursement applications and activated European clinical sites, identifying Germany as the probable site for the first commercial Prima implant.
Germany is expected to host the inaugural commercial Prima implant. Concurrently with its European launch, Science received two humanitarian use device designations from the FDA. These designations permit Prima’s use in patients with vision loss due to advanced geographic atrophy or Stargardt disease, a prerequisite for seeking approval via the humanitarian device exemption pathway.
The Series D funding will facilitate Science’s pursuit of FDA approval through this exemption pathway. Additionally, the company has allocated resources for expanding research, manufacturing, and operational capabilities. Funds will also support “substantial further investments” in its biohybrid program, which aims to develop a neural interface using living neurons to connect with the brain, potentially mitigating the risks associated with traditional wired implants.
